RASAZILECT rasagiline mesilate 1 mg tablets, blister

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

rasagiline mesilate, Quantity: 1.56 mg

Commercializzato da:

Arrotex Pharmaceuticals Pty Ltd

Forma farmaceutica:

Tablet, uncoated

Composizione:

Excipient Ingredients: purified talc; microcrystalline cellulose; maize starch; citric acid; silicon dioxide; pregelatinised maize starch; stearic acid

Via di somministrazione:

Oral

Confezione:

10, 30

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

Rasagiline is indicated for the symptomatic treatment of idiopathic Parkinsons disease (PD) as monotherapy (without concomitant levodopa/decarboxylase inhibitor therapy) or as adjunct therapy (with concomitant levodopa/decarboxylase inhibitor therapy).

Dettagli prodotto:

Visual Identification: White to off-white, round, flat bevelled tablets debossed with "C13" on one side and plain on the other side.; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 30 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Stato dell'autorizzazione:

Registered

Data dell'autorizzazione:

2018-01-23